- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Ligand families/groups||Immune checkpoint modulators|
|Approved drug?||Yes (FDA (2018))|
|International Nonproprietary Names|
|cemiplimab-rwlc | Libtayo® | REGN-2810 | REGN2810 | SAR-439684 | SAR439684|
|Cemiplimab (REGN2810) is a fully human anti-PD-1 immuno-oncology biological therapeutic that was developed by Regeneron Pharmaceuticals [1-2]. Preclinical in vitro and in vivo characterisation of the antibody was reported by Burova et al. in 2017 . Clinical trial results published in 2018  showed that ~50% of patients with advanced cutaneous squamous-cell carcinoma responded to treatment, with durable responses in 82% of responders with metastatic disease.
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.
|GtoPdb PubChem SID||381118800|
|Search PubMed clinical trials||cemiplimab|
|Search PubMed titles||cemiplimab|
|Search PubMed titles/abstracts||cemiplimab|